ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
SAN DIEGO, Aug. 4, 2011 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 31st Annual Canaccord Genuity Growth Conference on Thursday August 11th, 2011, at 3:30 pm Eastern time, in the Vancouver Room at the Intercontinental Hotel in Boston.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at http://www.adventrx.com/. An archived presentation will be available on the web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates. The Company's current lead product candidates are Exelbine and ANX-514, novel emulsion formulations of currently marketed chemotherapy drugs, and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. More information can be found on the Company's web site at http://www.adventrx.com/.
SOURCE ADVENTRX Pharmaceuticals, Inc.